About nuvectis pharma inc - NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
NVCT At a Glance
Nuvectis Pharma, Inc.
1 Bridge Plaza
Fort Lee, New Jersey 07024
| Phone | 1-201-614-3151 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -28,871,000.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NVCT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 10.528 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.825 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
NVCT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,220,846.154 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NVCT Liquidity
| Current Ratio | 2.385 |
| Quick Ratio | 2.385 |
| Cash Ratio | 2.379 |
NVCT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -114.759 |
| Return on Equity | -205.298 |
| Return on Total Capital | -156.797 |
| Return on Invested Capital | -205.298 |
NVCT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |